Dimerix Stock

Dimerix EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Dimerix (DXB.AX) as of Sep 4, 2026 is 5.87. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -39.20 — a change of -114.97% (higher).

EV/FCF

5.87

YoY

-114.97%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Dimerix is 2026 5.87 . EV/FCF (Enterprise Value to Free Cash Flow) of Dimerix was 2025 -39.20 . It decreases by -114.97% higher compared to the previous year.

The Dimerix EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-90.10 AUD
Jan 1, 2019
-106.48 AUD
Jan 1, 2020
-61.53 AUD
Jan 1, 2021
-46.63 AUD
Jan 1, 2022
-21.39 AUD
Jan 1, 2023
-23.18 AUD
Jan 1, 2024
-39.20 AUD
Jan 1, 2025
5.87 AUD
The Dimerix EV/FCF history
YEAREV/FCFYoY
5.87-114.97%
-39.20+69.10%
-23.18+8.38%
-21.39-54.13%
-46.63-24.21%
-61.53-42.21%
-106.48+18.18%
-90.10-42.97%
-157.98-26.08%
-213.73-59.77%
-531.26+2.30%
-519.29
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

EV/FCF (Enterprise Value to Free Cash Flow) of Dimerix is 5.87 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Dimerix changed from -39.20 to 5.87, representing a -114.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Dimerix since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Dimerix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Dimerix

All Key Metrics — Dimerix